Emerson v. Genocea Biosciences, Inc.

CourtDistrict Court, D. Massachusetts
DecidedFebruary 12, 2018
Docket1:17-cv-12137
StatusUnknown

This text of Emerson v. Genocea Biosciences, Inc. (Emerson v. Genocea Biosciences, Inc.) is published on Counsel Stack Legal Research, covering District Court, D. Massachusetts primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Emerson v. Genocea Biosciences, Inc., (D. Mass. 2018).

Opinion

UNITED STATES DISTRICT COURT DISTRICT OF MASSACHUSETTS

___________________________________ ) STEVEN EMERSON, individually ) and on behalf of all others ) Civil Action No. similarly situated; SHELDON ) 17-12137-PBS GRONER; BARRY HEANY; and ) MARK HANESS, ) Consolidated Cases: ) 17-12168-PBS Plaintiffs, ) 17-12474-PBS ) v. ) ) GENOCEA BIOSCIENCES, INC., WILLIAM ) D. CLARK, and JONATHAN POOLE, ) ) Defendants. ) ___________________________________)

MEMORANDUM AND ORDER

February 12, 2018

Saris, C.J.

INTRODUCTION

In this proposed class action, two competing lead plaintiffs allege securities fraud by a biopharmaceutical company. The plaintiffs assert that Genocea Biosciences, Inc. (“Genocea”) and two officers artificially inflated the company’s stock price by reporting overly optimistic prospects for a potential herpes treatment when, in reality, the company’s finances could not support successful regulatory approval of the drug. When the company later reported that it was abandoning the treatment, its share price fell precipitously. This prompted several plaintiffs to sue under the federal securities laws. Now before the Court are two competing motions to appoint a lead plaintiff and class counsel. After hearing and consideration of the parties’ submissions, the motion to appoint

the Genocea Investor Group as lead plaintiff with Scott+Scott, Attorneys at Law, LLP, and Levi & Korsinsky, LLP, as co-lead class counsel and Block & Leviton, LLP, as liaison counsel (Docket No. 22) is ALLOWED. The competing lead-plaintiff motion of Sheldon Groner (Docket No. 16) is DENIED. FACTUAL BACKGROUND Genocea is a biopharmaceutical company based in Cambridge, Massachusetts, that researches and develops vaccines and immunotherapies. Docket No. 1, ¶¶ 2-3, 18.1 Between May and September 2017, Genocea’s lead product candidate was a genital herpes immunotherapy product called GEN-003. Id. ¶¶ 1, 4, 19. The complaint alleges that the company and its officers made

materially false or misleading statements, or failed to disclose information about GEN-003 -- primarily that Genocea’s financial health was inadequate to support Phase 3 trials of the drug. Id.

1 This overview derives from the complaint in the lead case, Civil Action No. 17-12137-PBS. To the extent that the complaints in the two cases consolidated under the lead action vary, those variations are not material for present purposes. ¶ 5. As a result, the plaintiffs believe Genocea overstated the prospects of bringing GEN-003 to market. Id. For instance, in May 2017, Genocea disclosed that the company expected GEN-003 to be ready for Phase 3 trials by the fourth quarter of 2017. Id. ¶ 20. In July and August 2017, the

company made additional disclosures indicating positive results of Phase 2b trials and reiterating the company’s expectation that GEN-003 would soon be ready for Phase 3 trials. Id. ¶¶ 21- 22. However, after the markets closed on September 25, 2017, Genocea disclosed that it was halting spending on GEN-003, “exploring strategic alternatives for the drug,” and cutting 40 percent of its workforce. Id. ¶¶ 6, 23. The next day, the company’s share price fell $4.08, or 75 percent, to close at $1.25 per share. Id. ¶¶ 6, 24. The drop in Genocea’s share price prompted three putative class action lawsuits under §§ 10(b) and 20(a) of the Securities Exchange Act of 1934, 15 U.S.C. §§ 78j(b) and 78t(a), and under

Rule 10b-5, 17 C.F.R. § 240.10b-5. See id. ¶¶ 1, 26-50. At a hearing in January 2018, the Court allowed a motion to consolidate the three cases. The Court took under advisement competing motions for the appointment of a lead plaintiff and class counsel. Those motions are now ripe for decision. LEGAL STANDARDS I. General Framework for Appointing a Lead Plaintiff The Private Securities Litigation Reform Act (“PSLRA”) requires the Court to “appoint as lead plaintiff the member or members of the purported plaintiff class that the court determines to be most capable of adequately representing the interests of class members.” 15 U.S.C. § 78u-4(a)(3)(B)(i). A

class member may trigger a rebuttable presumption that she is the “most adequate plaintiff” by satisfying three criteria: (1) filing the complaint or making a timely motion to be lead plaintiff; (2) having the largest financial interest in the relief sought; and (3) otherwise satisfying Rule 23 of the Federal Rules of Civil Procedure. 15 U.S.C. § 78u- 4(a)(3)(B)(iii)(I). Another class member may rebut this presumption “only upon proof” that the presumptive “most adequate plaintiff” either (1) “will not fairly and adequately protect the interests of the class,” or (2) “is subject to unique defenses that render such plaintiff incapable of adequately representing the class.” 15 U.S.C. § 78u-

4(a)(3)(B)(iii)(II). II. Aggregating Plaintiffs to Form Largest Financial Interest When analyzing who has the “largest financial interest in the relief sought,” courts are divided on whether and when to allow groups of class members to aggregate their losses. See 7B Charles Alan Wright & Arthur R. Miller, Federal Practice and Procedure § 1806 (3d ed. 2017) (discussing various approaches and noting that “many courts have emphasized that the decision . . . must be made on a case-by-case basis”). See also Elizabeth Chamblee Burch, Optimal Lead Plaintiffs, 64 Vand. L. Rev. 1109, 1137–39 (2011) (describing various approaches). On one end of the spectrum, some courts have flatly refused to appoint groups

of unrelated persons as lead plaintiffs. See, e.g., In re Donnkenny Inc. Sec. Litig., 171 F.R.D. 156, 157–58 (S.D.N.Y. 1997) (ruling that “aggregation of unrelated plaintiffs to serve as lead plaintiffs defeats the purpose of choosing a lead plaintiff” and undermines PSLRA purpose of “prevent[ing] lawyer- driven litigation”). Others permit aggregation, taking note of the PSLRA’s direction to consider the “person or group of persons” with the largest financial interest in the case. See, e.g., In re Advanced Tissue Scis. Sec. Litig., 184 F.R.D. 346, 350 (S.D. Cal. 1998) (quoting 15 U.S.C. § 78u– 4(a)(3)(B)(iii)(I)). Still others fall somewhere in between. See Burch, supra, at 1138 (discussing courts that have appointed

groups where no bad faith exists, where the group has demonstrated cohesiveness, or where close-knit group members had pre-litigation relationships). In what appears to be the only Court of Appeals decision on point, the Third Circuit has adopted a “rule of reason” approach. See In re Cendant Corp. Litig., 264 F.3d 201, 266–67 (3d Cir. 2001). Noting that the PSLRA expressly permits a “group of persons” to serve as lead plaintiff, the Third Circuit “disagree[d] with those courts that have held that the statute invariably precludes a group of ‘unrelated individuals’ from serving as a lead plaintiff.” Id. at 266 (citing 15 U.S.C. §§

Related

Weisburgh v. Fidelity Magellan Fund
167 F.3d 735 (First Circuit, 1999)
In Re: Cendant Corporation Litigation
264 F.3d 201 (Third Circuit, 1992)
In Re Bank of Boston Corp. Securities Litigation
762 F. Supp. 1525 (D. Massachusetts, 1991)
Varghese v. China Shenghuo Pharmaceutical Holdings, Inc.
589 F. Supp. 2d 388 (S.D. New York, 2008)
Howard Gunty Profit Sharing Plan v. CareMatrix Corp.
354 F. Supp. 2d 18 (D. Massachusetts, 2000)
In Re Lernout & Hauspie Securities Litigation
138 F. Supp. 2d 39 (D. Massachusetts, 2001)
In Re Olsten Corp. Securities Litig.
3 F. Supp. 2d 286 (E.D. New York, 1998)
In Re Microstrategy Inc. Securities Litigation
110 F. Supp. 2d 427 (E.D. Virginia, 2000)
Reitan v. China Mobile Games & Entertainment Group, Ltd.
68 F. Supp. 3d 390 (S.D. New York, 2014)
Khunt v. Alibaba Group Holding Ltd.
102 F. Supp. 3d 523 (S.D. New York, 2015)
In re Petrobras Securities Litigation
104 F. Supp. 3d 618 (S.D. New York, 2015)
Arkansas Teacher Retirement System v. Insulet Corp.
177 F. Supp. 3d 618 (D. Massachusetts, 2016)
McKitty v. Advanced Tissue Sciences, Inc.
184 F.R.D. 346 (S.D. California, 1998)
Weltz v. Lee
199 F.R.D. 129 (S.D. New York, 2001)
Barnet v. Elan Corp.
236 F.R.D. 158 (S.D. New York, 2005)
In re Gentiva Securities Litigation
281 F.R.D. 108 (E.D. New York, 2012)
In re Donnkenny Inc. Securities Litigation
171 F.R.D. 156 (S.D. New York, 1997)

Cite This Page — Counsel Stack

Bluebook (online)
Emerson v. Genocea Biosciences, Inc., Counsel Stack Legal Research, https://law.counselstack.com/opinion/emerson-v-genocea-biosciences-inc-mad-2018.